

Supplementary Materials: Molecular Profiling of Endometrial Cancer: an Exploratory Study in Aotearoa, New Zealand





Figure S1. Example of insufficient staining patterns in autolysed endometrial tissue.



	Number of Cases, Total	Number of Events	Median Months Overall (95% CI)
Unaltered group	1241	189	NA
LAG3	47	11	NA
TIGIT	32	0	NA
CXCL13	4	3	27.27 (27.24 - NA)
CXCL9	8	2	30.11 (30.09 - NA)

Figure S2. Cbioportal output; Kaplan meier survival of altered immune genes identified in Figure 5; LAG3, TIGIT, CXCL13 and CXCL9.

Table S1. IHC conditions.

Antibody	MLH1	MSH2	MSH6	P53	PMS2	L1CAM
Control	Tonsil	Tonsil	Tonsil	Tonsil	Tonsil	Kidney
RTU/TITRATION	1:25	1:100	1:50	RTU	1:50	1:100
Clone	ES05	G219-1129	EP49	BP-53-11	EP51	14.1
Reference	M3640	286M-14	M3646	760-2542	M3647	L1
Supplier	DAKO (Denmark)	CELLMARQUE (USA)	DAKO (Denmark)	ROCHE (USA)	DAKO (Denmark)	Biolegend (USA)
Detection	Optiview DAB	Optiview DAB	Optiview DAB	Optiview DAB	Optiview DAB	Optiview DAB
HIER	CC1	CC1	CC1	CC1	CC1	CC1
HIER Temp	100	100	100	95	100	95
HIER Time	40	40	48	48	64	56
AB Time	32	16	32	20	24	32
Amp	N/A	Optiview AMP	N/A	N/A	Optiview AMP	n/a
Amp Time	N/A	4 minutes	N/A	N/A	4 minutes	n/a

Table S2. CTNNB1 mutations.

HGVS coding	HGVS Protein	Location	Sample number
c.110C>G	S37C	exon 3	22
c.101G>A	G34E	exon 3	26
c.110C>G	S37C	exon 3	32
c.101G>T	G34V	exon 3	39
c.110C>T	S37F	exon 3	35
c.94G>T	D32Y	exon 3	6
c.110C>T	S37F	exon 3	43
c.95A>T	D32V	exon 3	45
c.122C>T	T41I	exon 3	57
c.101G>T	G34V	exon 3	79
c.110C>T	S37F	exon 3	71

Table S3. Women who had recurrent endometrial cancer during the study period.

Histology	Stage	Grade	Subtype	Treatment	Recurrence (months)
E	IB	1	MMRd	Brachytherapy	33
E	IA	1	NSMP	clinical follow up only, radiotherapy upon recurrence	48
E	II	2	NSMP	Pelvic radiotherapy	8
E	II	2	MMRd	Chemoradiation therapy	27
E	IV	3	p53mut/POLE	Chemotherapy	passed away
E	IA	1	CTNNB1	clinical follow up only, radiotherapy upon recurrence	15
E	II	1	MMRd	Pelvic radiotherapy	19
E	IA	2	NSMP	clinical followup only	38
E	IA	2	NSMP	clinical follow up only	33
E	IVB	2	NSMP	declined treatment	passed away
E	IB	3	p53mut	Pelvic radiotherapy	13
E/S	IA	3	p53mut	declined treatment	18
S	IA	3	p53mut	Brachytherapy	15



© 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).